Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
PLRZ
Polyrizon Ltd.
Polyrizon Ltd. (PLRZ) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Value (C+).
Quantitative Factor Evaluation • Updated
Overall Rating
2.7
/ 5.0
C+
Value
C+
Factor Score
2.5
/ 5.0
Growth
C+
Factor Score
2.5
/ 5.0
Profitability
B-
Factor Score
3.0
/ 5.0
Momentum
C+
Factor Score
2.6
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
N/A
EV / EBITDA
-0.9
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
0.6%
Price Return 12M
117.7%
Catalyst Signal
0.00
Market Cap
$26.8M
TTM Revenue
N/A
Price / Sales
N/A
ROE
-21.4%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C+ (2.5) | C+ (2.5) | B- (3.0) | C+ (2.6) | C+ (2.6) | C+ (2.7) |
| 2026-11-07 | C+ (2.5) | C+ (2.5) | B- (3.0) | C (2.3) | C+ (2.7) | C+ (2.6) |
| 2026-10-31 | C+ (2.5) | C+ (2.5) | C- (2.1) | C+ (2.6) | C+ (2.7) | C (2.5) |
| 2026-10-24 | C+ (2.5) | C+ (2.5) | C- (2.1) | C- (1.9) | C+ (2.6) | C (2.3) |
| 2026-10-17 | C+ (2.5) | C+ (2.5) | C- (2.1) | C (2.4) | C+ (2.6) | C (2.4) |
Page
1
of
4